- $52.80m
- $28.54m
- $90.50m
Brief: Pulmonx Announces Closing Of Up To $60 Million Credit Facility
Pulmonx Q4 revenue beats expectations
Brief: Pulmonx Q4 EPS USD -0.25
Lung treatment firm Pulmonx's Q3 revenue up 5%, net loss narrows marginally
Brief: Pulmonx Q3 EPS USD -0.34
Brief: Pulmonx Announces Management Transition And Preliminary Third Quarter 2025 Revenue Reschedules Third Quarter 2025 Earnings Call To November 12, 2025
Brief: Pulmonx Corp - On October 21 Steven S. Williamson Resigned As President And CEO Of Pulmonx - SEC Filing
Brief: Pulmonx Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Pulmonx Corp reports results for the quarter ended June 30 - Earnings Summary
Pulmonx Q2 revenue up 15%, beats expectations, cuts FY revenue forecast
Pulmonx Corp expected to post a loss of 40 cents a share - Earnings Preview
Pulmonx Corp reports results for the quarter ended March 31 - Earnings Summary
Pulmonx Corp expected to post a loss of 40 cents a share - Earnings Preview
Pulmonx Corp reports results for the quarter ended December 31 - Earnings Summary
Brief: Pulmonx Q4 EPS USD -0.33
Pulmonx Corp expected to post a loss of 45 cents a share - Earnings Preview
Pulmonx Corp reports results for the quarter ended in January 1 - Earnings Summary
Brief: Pulmonx Q3 EPS USD -0.36
Pulmonx Corp expected to post a loss of 45 cents a share - Earnings Preview